Abstract 1603: Patient derived tumor organoids identify actionable targets in heavily pretreated metastatic breast cancer patients
Michael Churchill(Harvard University), Vijayakrishna K. Gadi(Fred Hutch Cancer Center), Kay E. Gurley(Fred Hutch Cancer Center), Carla Grandori(Precision for Medicine (United States)), Rachele Rosati(Precision for Medicine (United States)), Franz X. Schaub(Precision for Medicine (United States)), Christopher J. Kemp(Fred Hutch Cancer Center), Robert L. Diaz, Fengting Yan(The Ohio State University Wexner Medical Center), Reid Shaw(Precision for Medicine (United States)), Shalini Pereira(Precision for Medicine (United States)), Hallie A. Swan(Precision for Medicine (United States))
Cited by 0
Related Papers
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
|Annual Review of Cell and Developmental Biology|2000|1.3k
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
|Cancer Discovery|2017|964
Direct activation of TERT transcription by c-MYC
|Nature Genetics|1999|903
Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion
|Proceedings of the National Academy of Sciences|2000|827
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I
|Nature Cell Biology|2005|671